1800-272-662
Shopping Cart 0
countryflagAU
Login

Orthocell Ltd

Healthcare AU OCC

0.81AUD
-0.015(1.82%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.810.84
LowHigh

52 Week Range

0.771.70
LowHigh

Fundamentals

  • Previous Close 0.82
  • Market Cap223.83M
  • Volume421580
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.45096M
  • Revenue TTM9.33M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 5.95M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -11.75167M -10.23244M -9.41056M -11.25054M -11.43142M
Minority interest - - - - -
Net income -8.56664M -7.18096M -6.24818M -9.10659M -9.03702M
Selling general administrative 3.95M 3.61M 4.25M 2.24M 3.25M
Selling and marketing expenses 5.46M 3.09M 1.71M 3.30M 1.46M
Gross profit 4.80M 3.69M 3.22M 0.83M 0.39M
Reconciled depreciation 0.55M 0.52M 0.55M 0.35M 0.44M
Ebit -13.97548M -12.19820M -10.89467M -11.87323M -12.10495M
Ebitda -13.42795M -11.68112M -10.34055M -11.52461M -11.66929M
Depreciation and amortization 0.55M 0.52M 0.55M 0.35M 0.44M
Non operating income net other - - - - -
Operating income -13.97548M -11.68112M -10.28006M -11.52178M -11.63111M
Other operating expenses 21.53M 17.00M 14.50M 12.87M 12.65M
Interest expense - 0.06M - 0.08M 0.67M
Tax provision -3.18503M -3.05148M -3.16238M -2.14396M -2.39440M
Interest income 1.30M 1.03M 0.85M 0.08M 0.20M
Net interest income 1.25M 0.97M 0.85M 0.08M 0.20M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.18503M -3.05148M -3.16238M -2.14396M -2.39440M
Total revenue 7.55M 5.32M 4.24M 1.53M 1.02M
Total operating expenses 18.78M 15.37M 14.11M 12.70M 12.50M
Cost of revenue 2.75M 1.63M 1.03M 0.70M 0.63M
Total other income expense net 2.22M 1.45M 0.08M 0.19M 0.04M
Discontinued operations - - - - -
Net income from continuing ops -8.56664M -7.18096M -6.24818M -9.10659M -9.03702M
Net income applicable to common shares -8.56664M -7.18096M -6.24818M -9.10659M -9.03702M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 35.24M 26.62M 29.61M 37.90M 19.33M
Intangible assets 1.07M 1.05M 1.13M 1.23M 1.32M
Earning assets - - - - -
Other current assets 0.20M 0.00971M 0.17M 0.08M 0.01M
Total liab 20.67M 22.08M 23.46M 27.99M 2.46M
Total stockholder equity 14.57M 4.53M 6.15M 9.90M 16.87M
Deferred long term liab - - - - -
Other current liab 2.08M 1.50M 1.17M 2.63M 0.30M
Common stock 83.49M 62.22M 57.90M 57.48M 55.78M
Capital stock 83.49M 62.22M 57.90M 57.48M 55.78M
Retained earnings -74.07040M -65.62639M -59.08434M -53.48536M -45.11498M
Other liab - - 18.54M 20.79M 0.01M
Good will - - - - -
Other assets - - - - -
Cash 28.62M 20.61M 24.82M 11.02M 16.33M
Cash and equivalents - - 24.82M 11.02M 16.33M
Total current liabilities 6.40M 5.31M 4.53M 6.82M 1.93M
Current deferred revenue 2.30M 2.30M 2.30M 0.78M 0.63M
Net debt -28.04303M -19.92475M -24.25566M -10.51399M -15.70719M
Short term debt 0.33M 0.15M 0.18M 0.12M 0.11M
Short long term debt - - - - -
Short long term debt total 0.58M 0.69M 0.56M 0.51M 0.62M
Other stockholder equity - - -1.89339M -7.07045M -13.74093M
Property plant equipment - - 1.61M 1.40M 0.93M
Total current assets 31.83M 23.01M 26.87M 35.26M 17.07M
Long term investments - - - - -
Net tangible assets - - 5.02M 8.67M 15.55M
Short term investments - - - - -
Net receivables 1.81M 1.21M 0.84M 23.55M 0.26M
Long term debt - - - - -
Inventory 1.20M 1.18M 1.03M 0.61M 0.47M
Accounts payable 1.69M 1.35M 0.88M 3.28M 0.89M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.15M 7.94M 7.34M 5.91M 6.21M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 1.05M -2.73911M -2.63184M -2.25797M
Deferred long term asset charges - - - - -
Non current assets total 3.40M 3.61M 2.74M 2.63M 2.26M
Capital lease obligations 0.58M 0.69M 0.56M 0.51M 0.62M
Long term debt total - - 0.38M 0.39M 0.51M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.35906M -0.94202M -0.63156M -0.53502M -0.18852M
Change to liabilities - - -2.98300M 25.27M 0.11M
Total cashflows from investing activities -0.35906M -0.94202M -0.63156M -0.53502M -0.18852M
Net borrowings - - -0.16461M -0.14682M -0.11545M
Total cash from financing activities 17.05M 3.24M -0.16461M 1.49M 0.71M
Change to operating activities - - 0.22M 0.10M -0.08837M
Net income -8.56664M -7.18096M -6.24818M -9.10659M -9.03702M
Change in cash 8.01M -4.20352M 13.80M -5.30736M -4.11270M
Begin period cash flow 20.61M 24.82M 11.02M 16.33M 20.44M
End period cash flow 28.62M 20.61M 24.82M 11.02M 16.33M
Total cash from operating activities -8.68293M -6.50513M 14.59M -6.26146M -4.51788M
Issuance of capital stock - - - 1.64M 0.71M
Depreciation - 0.52M 0.55M 0.35M 0.44M
Other cashflows from investing activities -0.09864M -0.01513M - - -
Dividends paid - - - - -
Change to inventory -0.06823M -0.16503M -0.44068M -0.14682M -0.44541M
Change to account receivables -0.51967M -0.32399M 20.95M -23.25081M -0.01093M
Sale purchase of stock -0.88200M -0.12258M - 1.64M 0.71M
Other cashflows from financing activities 17.93M 3.24M -0.16461M -0.14682M -0.18852M
Change to netincome - - 2.54M 0.52M 4.40M
Capital expenditures 0.36M 0.94M 0.63M 0.54M 0.19M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.29974M -1.94274M 20.51M -23.39763M -0.45634M
Stock based compensation - 2.10M 2.49M 0.50M 4.30M
Other non cash items -6.38319M 2.10M 20.29M 2.50M 4.08M
Free cash flow -9.04198M -7.44714M 13.96M -6.79648M -4.70640M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OCC
Orthocell Ltd		 -0.015 1.82% 0.81 - - 23.99 25.01 17.09 -3.8756
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

Orthocell Ltd

Building 191, Murdoch, WA, Australia, 6150

Key Executives

Name Title Year Born
Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D. Exec. Chairman 1970
Mr. Paul Frederick Anderson CEO, MD & Exec. Director 1966
Ms. Leslie Wise J.D. Exec. Director NA
Ms. Nicole Jane Telford Chief Financial Officer NA
Mr. Alex McHenry Chief Operating Officer NA
Prof. Ming Hao Zheng Chief Scientific Officer and Member of Medical & Scientific Advisory Board NA
Mr. Simon Lee Robertson B.Bus, C.A., CA, M Appl. Fin. Company Sec. 1960
Mr. Paul Frederick Anderson CEO, MD & Executive Director 1966
Mr. Tony Macintyre Chief Manufacturing Officer NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.